<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00024310</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068917</org_study_id>
    <secondary_id>UCLA-0005068</secondary_id>
    <secondary_id>TULA-T3004</secondary_id>
    <secondary_id>NCI-G01-2017</secondary_id>
    <nct_id>NCT00024310</nct_id>
  </id_info>
  <brief_title>Paclitaxel, Folic Acid, and Lometrexol in Treating Patients With Locally Advanced or Metastatic Solid Tumors</brief_title>
  <official_title>A Phase I Trial of Lometrexol Sodium and Paclitaxel Adminsitered Intravenously Every 21 Days in Conjunction With Oral Folic Acid in Patients With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Folic acid may protect normal cells from the side effects of&#xD;
      chemotherapy and may increase the effectiveness of chemotherapy by making tumor cells more&#xD;
      sensitive to the drug. Lometrexol may stop the growth of tumors by blocking one of the&#xD;
      enzymes necessary for cancer cell growth. Combining chemotherapy with folic acid and&#xD;
      lometrexol may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of combining paclitaxel, folic acid, and&#xD;
      lometrexol in treating patients who have locally advanced or metastatic solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose and recommended phase II study dose of lometrexol&#xD;
           and paclitaxel when combined with folic acid in patients with locally advanced or&#xD;
           metastatic solid tumors.&#xD;
&#xD;
        -  Determine the quantitative and qualitative toxic effects of this regimen in these&#xD;
           patients.&#xD;
&#xD;
        -  Determine the plasma concentrations of lometrexol and paclitaxel and relate their&#xD;
           pharmacokinetics to toxicity outcome in these patients.&#xD;
&#xD;
        -  Determine the antitumor activity of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter, dose-escalation study of lometrexol and paclitaxel.&#xD;
&#xD;
      Patients receive lometrexol IV over 30-60 seconds immediately followed by paclitaxel IV over&#xD;
      3 hours on day 1. Patients also receive oral folic acid beginning 7 days before&#xD;
      lometrexol/paclitaxel and continuing for 14 days. Treatment repeats every 21 days in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Doses of lometrexol and paclitaxel are escalated sequentially. Cohorts of 3-6 patients&#xD;
      receive escalating doses of lometrexol and paclitaxel until the maximum tolerated dose (MTD)&#xD;
      is determined. The MTD is defined as the dose at which at least 2 of 6 patients experience&#xD;
      dose-limiting toxicity. Six to twelve additional patients are treated at the recommended&#xD;
      phase II study dose (dose immediately preceding the MTD).&#xD;
&#xD;
      Patients are followed every 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 12-42 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>September 2001</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Drug/Agent Toxicity by Tissue/Organ</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>folic acid</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lometrexol</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically proven locally advanced or metastatic solid tumor that&#xD;
             is refractory to standard therapies or for which there are no therapies of potential&#xD;
             major benefit&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  No hematologic malignancies, including leukemia, lymphoma, or multiple myeloma&#xD;
&#xD;
          -  No symptomatic effusions or ascites unless drained before study entry&#xD;
&#xD;
          -  No clinically apparent CNS metastases or carcinomatous meningitis&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  WHO 0-1&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3*&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3*&#xD;
&#xD;
          -  Hemoglobin at least 9.0 g/dL* NOTE: * Without growth factor support&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 mg/dL&#xD;
&#xD;
          -  SGOT and SGPT no greater than 2.5 times upper limit of normal (ULN) (5 times ULN if&#xD;
             tumor involvement of liver)&#xD;
&#xD;
          -  Albumin greater than 2.5 g/dL&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Glomerular filtration rate at least 65 mL/min&#xD;
&#xD;
        Gastrointestinal:&#xD;
&#xD;
          -  No inflammatory bowel disease&#xD;
&#xD;
          -  No radiation enteritis&#xD;
&#xD;
          -  No malabsorption syndrome&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No known hypersensitivity to study drugs or related compounds (e.g., LY309887,&#xD;
             multi-targeted antifolate, AG-2034, methotrexate, docetaxel, or polyoxyethylated&#xD;
             castor oil)&#xD;
&#xD;
          -  No active uncontrolled infection unless approved by the investigator&#xD;
&#xD;
          -  No other severe concurrent disease that would preclude study therapy&#xD;
&#xD;
          -  No body surface area greater than 3.0 m^2&#xD;
&#xD;
          -  No known vitamin B12 deficiency&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No concurrent routine or prophylactic filgrastim (G-CSF), sargramostim (GM-CSF), or&#xD;
             epoetin alfa&#xD;
&#xD;
          -  No concurrent biologic-response modifiers&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for mitomycin, carboplatin, or&#xD;
             nitrosourea) and recovered&#xD;
&#xD;
          -  No other concurrent cytotoxic chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No concurrent hormonal therapy&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Recovered from prior radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy to 25% or more of bone marrow (e.g., whole-pelvic irradiation)&#xD;
&#xD;
          -  No concurrent radiotherapy (including palliative radiotherapy)&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  At least 4 weeks since prior major surgery and recovered&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 4 weeks since prior investigational agent&#xD;
&#xD;
          -  No more than 2 prior therapies for locally advanced or metastatic solid tumor&#xD;
&#xD;
          -  No other concurrent investigational agent&#xD;
&#xD;
          -  No concurrent trimethoprim, co-trimoxazole, proguanil, or pyrimethamine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lee S. Rosen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center, UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2002</verification_date>
  <study_first_submitted>September 13, 2001</study_first_submitted>
  <study_first_submitted_qc>June 19, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2003</study_first_posted>
  <last_update_submitted>September 16, 2013</last_update_submitted>
  <last_update_submitted_qc>September 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2013</last_update_posted>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>drug/agent toxicity by tissue/organ</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Drug-Related Side Effects and Adverse Reactions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Lometrexol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

